Even though regulatory bodies like the EMA and FDA cannot work in tandem with industry and academia, they do share a common goal: to develop and launch new drugs that improve society's wellbeing.

TI Pharma brings all stakeholders to the same table. It acts as a neutral platform where common ground can be created and conflicting interests can be mediated, jointly working towards an improved and innovation-friendly regulatory framework.

“TI Pharma's program managers are experts in the content, enabling them to keep parties focused on the goals that were agreed upon at the outset.”

Jan Raaijmakers
Past VP External Scientific Collaborations GSK Europe
Chair TI Pharma Board of Directors

Share this page: